SWOT Analysis for Piramal Pharma Ltd. - Weakness

Add SWOT widget to your site/app

Stocks in Buy Zone with High Momentum Score Last Month

Relative Outperformance versus Industry over 1 Year

Companies with high TTM EPS Growth

Growth Stars: Strongest Annual EPS Performers

Expensive Performers (DVM)

Annual Profit Growth higher than Sector Profit Growth

PEG lower than Industry PEG

Companies with rising net profit margins - quarterly as well as TTM basis

Effectively using its capital to generate profit - RoCE improving in last 2 years

Effectively using Shareholders fund - Return on equity (ROE) improving since last 2 year

Efficient in managing Assets to generate Profits - ROA improving since last 2 year

Growth in Net Profit with increasing Profit Margin (QoQ)

Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Annual Net Profits improving for last 2 years

Book Value per share Improving for last 2 years

Companies with Zero Promoter Pledge

High Volume, High Gain

Top Gainers

Volume Shockers

PE higher than Industry PE

High PE (PE > 40)

Bearish Stocks - Stocks with Medium to Low Trendlyne Momentum Score

Stocks with Expensive Valuations according to the Trendlyne Valuation Score

Declining Net Cash Flow : Companies not able to generate net cash

Weak Momentum: Price below Short, Medium and Long Term Averages

Increasing Trend in Non-Core Income

Stocks Underperforming their Industry Price Change in the Quarter

Mutual Funds Increased Shareholding in Past Month

Street Favorite: High Analyst Rating with at least 20% upside

Highest FII stock holdings

FII / FPI or Institutions increasing their shareholding

MFs increased their shareholding last quarter

Mutual Funds Increased Shareholding over the Past Two Months

Mf buying for 2 months

Broker downgrades in price or recommendation in the past one month

Expensive Performers (DVM)